Drug profile · INN
paltusotine hydrochloride
PALSONIFY
paltusotine hydrochloride (PALSONIFY) is an FDA-listed pharmaceutical active ingredient. Associated with Crinetics Pharmaceuticals Europe GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — paltusotine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 9
- Programs
- 2
- Data quality
- 0.89
Quick answer
paltusotine hydrochloride (PALSONIFY) is an FDA-listed pharmaceutical active ingredient. Associated with Crinetics Pharmaceuticals Europe GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Crinetics Reports $10.3M Palsonify Sales Amid 232 Enrollment Updates
Crinetics Pharmaceuticals reports $10.3M in Palsonify sales and updates on 232 enrollment forms. This article explores the implications for investors and BD teams.
Crinetics Pharmaceuticals Receives EU Approval for PALSONIFY (Paltusotine), First Oral Daily Acromegaly Treatment
Crinetics Pharmaceuticals announces European Commission approval of PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly in adults.
Pipeline programs
Related patents
-
US 12208092
Compositions and methods for administering paltusotine to patients with hepatic impairment
granted -
US 11957674
Formulations of a somatostatin modulator
granted -
US 11414397
Somatostatin modulators and uses thereof
granted -
US 11266641
Formulations of a somatostatin modulator
granted -
US 10875839
Somatostatin modulators and uses thereof
granted -
US 10597377
Somatostatin modulators and uses thereof
granted -
US 10464918
Process of making somatostatin modulators
granted -
US 10351547
Somatostatin modulators and uses thereof
granted -
US 9896432
Somatostatin modulators and uses thereof
granted
Frequently asked questions
What is paltusotine hydrochloride?
paltusotine hydrochloride (PALSONIFY) is an FDA-listed pharmaceutical active ingredient. Associated with Crinetics Pharmaceuticals Europe GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for paltusotine hydrochloride?
PALSONIFY is a marketed brand name for paltusotine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of paltusotine hydrochloride?
paltusotine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.